Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Fallopian tube cancer

113 clinical trials

118 products

19 drugs

1 abstract

Clinical trial
A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
23ME-00610
Clinical trial
Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)
Status: Recruiting, Estimated PCD: 2027-04-27
Product
REGN5668
Product
Cemiplimab
Product
REGN4018
Product
Sarilumab
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CDX-585
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Product
Chemotherapy
Product
TRK-950
Product
Niraparib
Clinical trial
A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Niraparib in Japanese Patients With Platinum-sensitive, Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Achieved CR or PR in the Last Chemotherapy Containing Platinum-based Anticancer Agents
Status: Completed, Estimated PCD: 2019-03-17
Clinical trial
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
CDX-1140
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Pembrolizumab
Product
MDNA11
Product
entinostat
Product
avelumab
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Status: Completed, Estimated PCD: 2019-02-21
Product
XMT-1660
Product
Placebo
Product
CDX-301
Product
pembrolizumab
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Irinotecan
Product
Leucovorin
Product
5-FU
Product
Cisplatin
Product
Ramucirumab
Product
Nivolumab
Product
Gemcitabine
Product
Carboplatin
Product
Paclitaxel
Product
NM21-1480
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-06
Product
Bevacizumab
Product
Imiquimod
Product
PLD
Product
ATX-101 + Carboplatin + Pegylated liposomal doxorubicin
Clinical trial
Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2023-11-30
Clinical trial
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Status: Recruiting, Estimated PCD: 2025-06-30
Product
ONC-392
Clinical trial
A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients With Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers
Status: , Estimated PCD: 2024-07-01
Product
Mirvetuximab + SL-172154
Clinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-12-02
Product
CART-TnMUC1
Product
Pegylated Liposomal Doxorubicin
Product
PF-06873600
Clinical trial
PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY
Status: Active (not recruiting), Estimated PCD: 2023-04-05
Product
Endocrine Therapy
Product
Fludarabine
Product
Cyclophosphamide
Clinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Pegfilgrastim
Product
Topotecan
Product
Mirvetuximab soravtansine
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status: Completed, Estimated PCD: 2021-03-12
Product
Luveltamab
Product
Mirvetuximab
Clinical trial
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Status: Terminated, Estimated PCD: 2024-02-15
Product
Maplirpacept
Product
ATX-101
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Status: Recruiting, Estimated PCD: 2024-06-30
Product
IMGN151
Clinical trial
Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
Status: Recruiting, Estimated PCD: 2025-06-06
Drug
Atezolizumab
Drug
Tiragolumab
Product
Pegylated liposomal doxorubicin
Clinical trial
A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Advanced High Grade Serous Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Sovilnesib
Clinical trial
Multicenter, Open-label, ph 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Status: Active (not recruiting), Estimated PCD: 2024-01-17
Clinical trial
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-10-19
Product
DSP-7888
Product
Mirvetuximab soravtansine plus Bevacizumab
Clinical trial
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
HS-20089
Clinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
ART0380
Clinical trial
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
Status: Completed, Estimated PCD: 2023-03-08
Product
Rucaparib
Clinical trial
A Single-arm, Phase III Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer With High Expression of Folate Receptor-α
Status: Recruiting, Estimated PCD: 2023-04-30
Clinical trial
A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2017-05-01
Product
IMNN-001
Clinical trial
Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects With Ovarian Cancer
Status: Completed, Estimated PCD: 2023-02-02
Product
Mirvetuximab Soravtansine
Product
ADCT-301
Product
SL-172154
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status: Completed, Estimated PCD: 2023-02-16
Product
XmAb®22841
Clinical trial
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2021-05-26
Clinical trial
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-12-08
Clinical trial
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Status: Completed, Estimated PCD: 2021-11-16
Clinical trial
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor
Status: Completed, Estimated PCD: 2019-03-01
Clinical trial
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2018-05-14
Product
niraparib
Clinical trial
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Status: Recruiting, Estimated PCD: 2024-08-01
Product
STRO-002
Product
Atezolizumab
Clinical trial
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Status: Terminated, Estimated PCD: 2023-09-29
Product
Upifitimab
Product
TG4050
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AI-061
Clinical trial
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Status: Terminated, Estimated PCD: 2020-08-24
Clinical trial
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Status: Completed, Estimated PCD: 2017-04-01
Clinical trial
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Status: Completed, Estimated PCD: 2021-12-31
Product
GL-ONC1
Clinical trial
A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Status: Completed, Estimated PCD: 2019-11-05
Product
ZN-c3
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Status: Completed, Estimated PCD: 2022-02-08
Product
CDX-527
Product
Tisotumab Vedotin
Clinical trial
KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Zirabev
Clinical trial
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Status: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
Status: Not yet recruiting, Estimated PCD: 2025-05-16
Product
KAND567
Product
Olaparib
Clinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
Docetaxel
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
Status: Completed, Estimated PCD: 2019-01-31
Clinical trial
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2020-12-02
Product
Tremelimumab
Clinical trial
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib as Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
GM-CSF
Product
Dendritic Cell/Tumor Fusion Vaccine
Drug
imiquimod
Clinical trial
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2020-09-29
Product
Autologous Monocytes + ACTIMMUNE + SYLATRON
Clinical trial
A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-12
Product
DPX-Survivac
Drug
cyclophosphamide
Clinical trial
Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)
Status: Recruiting, Estimated PCD: 2028-02-01
Drug
AN0025
Clinical trial
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Status: Terminated, Estimated PCD: 2022-11-30
Product
Talazoparib
Clinical trial
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The t-BRCA Study
Status: Active (not recruiting), Estimated PCD: 2025-11-01
Product
Somatic and Germline BRCA1/2 Testing
Clinical trial
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2018-10-08
Product
Ketorolac
Clinical trial
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Not yet recruiting, Estimated PCD: 2028-06-30
Product
FT536
Clinical trial
A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Status: Completed, Estimated PCD: 2022-12-29
Product
Ixabepilone
Clinical trial
MT2021-27 Intraperitoneal FT538 With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: , Estimated PCD: 2026-09-30
Product
FT538
Drug
Enoblituzumab
Clinical trial
Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Re-stimulated TILs
Drug
IL-2
Clinical trial
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Completed, Estimated PCD: 2011-01-24
Product
ALVAC-NY-ESO-1-TRICOM vaccine
Clinical trial
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Completed, Estimated PCD: 2019-05-15
Drug
carboplatin
Drug
paclitaxel
Product
Pazopanib
Clinical trial
A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas
Status: Completed, Estimated PCD: 2021-08-03
Product
filgrastim
Product
Therapeutic autologous lymphocytes
Clinical trial
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2027-08-01
Product
Adjuvant Chemotherapy
Drug
Cisplatin
Clinical trial
Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2026-08-30
Drug
IMNN-001
Clinical trial
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Status: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Completed, Estimated PCD: 2006-05-09
Product
NY-ESO-1
Clinical trial
A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-03-10
Product
Fluzoparib
Product
Fluzoparib+Apatinib
Clinical trial
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2024-03-26
Product
MOv19-BBz CAR T cells
Clinical trial
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Placebos
Clinical trial
An Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Bevacizumab for Maintenance Therapy After First-line Platinum-containing Chemotherapy in BRCA Wild-type Advanced Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Platinum-based Chemotherapy
Product
Dostarlimab
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184
Clinical trial
A Surgical Window Pilot Investigation of Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
Status: Active (not recruiting), Estimated PCD: 2022-05-06
Product
Aspirin
Clinical trial
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Completed, Estimated PCD: 2009-05-01
Product
rV-NY-ESO-1
Product
rF-NY-ESO-1 vaccine
Clinical trial
A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2029-12-01
Drug
ZEN003694
Clinical trial
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
Status: Completed, Estimated PCD: 2016-03-10
Product
cisplatin
Clinical trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2021-02-28
Product
Paclitaxel + Carboplatin
Clinical trial
BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Product
Cobimetinib
Clinical trial
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Status: Active (not recruiting), Estimated PCD: 2015-02-25
Drug
UTD1
Drug
mFOLFOX6
Clinical trial
Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer
Status: Withdrawn, Estimated PCD: 2023-02-22
Clinical trial
Safety and Efficacy of High Dose Inorganic seLenium for Preventing Chemotherapy Induced pEripheral Neuropathy in platINUM Sensitive Recurrent Ovarian, Fallopian, Primary Peritoneal Cancer: Phase III Randomised Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2023-04-30
Product
Sodium Selenite
Drug
Varlilumab
Clinical trial
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Drug
T-VEC
Drug
Lurbinectedin
Clinical trial
Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2011-04-21
Product
celecoxib
Clinical trial
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
Status: Recruiting, Estimated PCD: 2026-04-15
Drug
olaparib
Clinical trial
Efficacy and Safety of Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer: a Single-center Prospective Single-arm Study
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study
Status: Recruiting, Estimated PCD: 2025-06-17
Product
Propranolol
Clinical trial
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Status: Terminated, Estimated PCD: 2022-09-01
Product
Huaier
Product
Etodolac
Clinical trial
Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-17
Clinical trial
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
3 cycles chemotherapy
Product
6 cycles chemotherapy
Clinical trial
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
Status: Recruiting, Estimated PCD: 2023-12-15
Clinical trial
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Microdevice
Clinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
huCART-meso
Clinical trial
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
Status: Terminated, Estimated PCD: 2024-04-01
Product
AVB-001
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20192
Product
ZN-c3 + carboplatin
Product
ZN-c3 + chemotherapy
Clinical trial
A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Not yet recruiting, Estimated PCD: 2028-07-31